A mirtazapin hatása a krónikus tenziós típusú fejfájásban szenvedõ betegekre. Irodalmi attekintés.

Translated title of the contribution: Effects of mirtazapine in patients with chronic tension-type headache. Literature review

J. Tajti, János Almási

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

On the basis of the criteria of the International Headache Society (IHS) tension-type headache (TTH) is classed among the primary headaches. The independent headache diseases are characterized with the type of headache and with the concomitant symptoms. Among the independent headaches TTH has the highest prevalence (38.3%). The prevalence which is the highest between the age of 30 and 39, in women is higher (46,9%) than is men (42.3%). The diagnosis of TTH is not automatically mean the diagnosis of depression. Depression can occur as a comorbid disease. In episodic TTH the prevalence of depression is 32%, while in chronic TTH it is 40%. The prophylactic treatment of patients suffering from chronic TTH has not been solved yet. On the basis of a double-blind, placebo-controlled study mirtazapine is said to be a good opportunity in the treatment of patients with chronic TTH, as it improved the status of the patients with 34% (AUC: Area Under the headache Curve calculated from the product of the period and the intensity of headache), moreover mirtazapine decreased the frequency, intensity and duration of headache as well. The favourable effects of mirtazapine is explained beyond its serotonergic and noradrenergic dual mode of action with its antinociceptive effects which is presumably fulfilled via 3-opioid receptors.

Original languageHungarian
Pages (from-to)67-72
Number of pages6
JournalNeuropsychopharmacologia Hungarica
Volume8
Issue number2
Publication statusPublished - Jun 2006

Fingerprint

Tension-Type Headache
Headache Disorders
Headache
Area Under Curve
mirtazapine
Opioid Receptors
Placebos
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A mirtazapin hatása a krónikus tenziós típusú fejfájásban szenvedõ betegekre. Irodalmi attekintés. / Tajti, J.; Almási, János.

In: Neuropsychopharmacologia Hungarica, Vol. 8, No. 2, 06.2006, p. 67-72.

Research output: Contribution to journalArticle

@article{f23b54b62f2345c3995903b704de87ed,
title = "A mirtazapin hat{\'a}sa a kr{\'o}nikus tenzi{\'o}s t{\'i}pus{\'u} fejf{\'a}j{\'a}sban szenved{\~o} betegekre. Irodalmi attekint{\'e}s.",
abstract = "On the basis of the criteria of the International Headache Society (IHS) tension-type headache (TTH) is classed among the primary headaches. The independent headache diseases are characterized with the type of headache and with the concomitant symptoms. Among the independent headaches TTH has the highest prevalence (38.3{\%}). The prevalence which is the highest between the age of 30 and 39, in women is higher (46,9{\%}) than is men (42.3{\%}). The diagnosis of TTH is not automatically mean the diagnosis of depression. Depression can occur as a comorbid disease. In episodic TTH the prevalence of depression is 32{\%}, while in chronic TTH it is 40{\%}. The prophylactic treatment of patients suffering from chronic TTH has not been solved yet. On the basis of a double-blind, placebo-controlled study mirtazapine is said to be a good opportunity in the treatment of patients with chronic TTH, as it improved the status of the patients with 34{\%} (AUC: Area Under the headache Curve calculated from the product of the period and the intensity of headache), moreover mirtazapine decreased the frequency, intensity and duration of headache as well. The favourable effects of mirtazapine is explained beyond its serotonergic and noradrenergic dual mode of action with its antinociceptive effects which is presumably fulfilled via 3-opioid receptors.",
author = "J. Tajti and J{\'a}nos Alm{\'a}si",
year = "2006",
month = "6",
language = "Hungarian",
volume = "8",
pages = "67--72",
journal = "Neuropsychopharmacologia Hungarica",
issn = "1419-8711",
publisher = "Hungarian Association of Psychopharmacology",
number = "2",

}

TY - JOUR

T1 - A mirtazapin hatása a krónikus tenziós típusú fejfájásban szenvedõ betegekre. Irodalmi attekintés.

AU - Tajti, J.

AU - Almási, János

PY - 2006/6

Y1 - 2006/6

N2 - On the basis of the criteria of the International Headache Society (IHS) tension-type headache (TTH) is classed among the primary headaches. The independent headache diseases are characterized with the type of headache and with the concomitant symptoms. Among the independent headaches TTH has the highest prevalence (38.3%). The prevalence which is the highest between the age of 30 and 39, in women is higher (46,9%) than is men (42.3%). The diagnosis of TTH is not automatically mean the diagnosis of depression. Depression can occur as a comorbid disease. In episodic TTH the prevalence of depression is 32%, while in chronic TTH it is 40%. The prophylactic treatment of patients suffering from chronic TTH has not been solved yet. On the basis of a double-blind, placebo-controlled study mirtazapine is said to be a good opportunity in the treatment of patients with chronic TTH, as it improved the status of the patients with 34% (AUC: Area Under the headache Curve calculated from the product of the period and the intensity of headache), moreover mirtazapine decreased the frequency, intensity and duration of headache as well. The favourable effects of mirtazapine is explained beyond its serotonergic and noradrenergic dual mode of action with its antinociceptive effects which is presumably fulfilled via 3-opioid receptors.

AB - On the basis of the criteria of the International Headache Society (IHS) tension-type headache (TTH) is classed among the primary headaches. The independent headache diseases are characterized with the type of headache and with the concomitant symptoms. Among the independent headaches TTH has the highest prevalence (38.3%). The prevalence which is the highest between the age of 30 and 39, in women is higher (46,9%) than is men (42.3%). The diagnosis of TTH is not automatically mean the diagnosis of depression. Depression can occur as a comorbid disease. In episodic TTH the prevalence of depression is 32%, while in chronic TTH it is 40%. The prophylactic treatment of patients suffering from chronic TTH has not been solved yet. On the basis of a double-blind, placebo-controlled study mirtazapine is said to be a good opportunity in the treatment of patients with chronic TTH, as it improved the status of the patients with 34% (AUC: Area Under the headache Curve calculated from the product of the period and the intensity of headache), moreover mirtazapine decreased the frequency, intensity and duration of headache as well. The favourable effects of mirtazapine is explained beyond its serotonergic and noradrenergic dual mode of action with its antinociceptive effects which is presumably fulfilled via 3-opioid receptors.

UR - http://www.scopus.com/inward/record.url?scp=34548477123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548477123&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 67

EP - 72

JO - Neuropsychopharmacologia Hungarica

JF - Neuropsychopharmacologia Hungarica

SN - 1419-8711

IS - 2

ER -